J&J Signs $509M Deal with Swiss Biotech for Alzheimer’s Vax

Jan 13, 2015

Bidness Etc

Johnson and Johnson, in a bid to boost its Alzheimer's R&D program, struck a deal potentially worth up to $509 million with Swiss-based biotech AC Immune to develop anti-tau vaccines.

The hope is that therapeutic vaccines targeting tau -- one of two abnormal proteins tied to the memory-robbing disease -- will offer a way to treat Alzheimer’s patients earlier. There is still no treatment that can slow the progression of the disease, with current drugs only easing symptoms of the disorder.

Johnson & Johnson will also further develop AC Immune's lead therapeutic vaccine, ACI-35, which is currently in an early-stage Phase IB clinical trial.

Read the Bidness Etc article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments